Schizophrenia.com

Neurocrine Biosciences & Sosei Group Collaborate to Develop Treatment for Neuropsychiatric Disorders

https://www.contractpharma.com/contents/view_breaking-news/2021-11-22/neurocrine-biosciences-sosei-group-collaborate-to-develop-treatment-for-neuropsychiatric-disorders/

Neurocrine Biosciences Inc. and Sosei Group Corporation have signed a strategic collaboration and licensing agreement to develop novel muscarinic receptor agonists, which Neurocrine Biosciences intends to study in the treatment for schizophrenia, dementia and other neuropsychiatric disorders.

I don’t know much about “novel muscarinic receptor agonists”. But at least they’re still trying to develop new meds.

1 Like
2 Likes

Thats what I was going to say, Karuna’s KarXT act on muscarinic receptors and is in clinical phase 3 testing so its almost out.

1 Like

I hope these new generation APs that dont act on dopamine receptors help negative symptoms.

2 Likes

Muscarinic receptor effect to schizo had been identified in 1970s its old science with new technology to combat its side effect, taar1 is more recent in 2001 iirc

1 Like